Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial
Summary
Background Bifidobacterium bifidum MIMBb75 is one of a few probiotic strains that have been shown to be effective inthe treatment of irritable bowel syndrome (IBS) and its symptoms. Non-viable strains might have advantages over viablebacteria for product stability and standardisation, as well as for tolerability because safety concerns have been raised forspecific patient groups who are susceptible to infection. We aimed to assess the efficacy of non-viable, heat-inactivated(HI) B bifidum MIMBb75 (SYN-HI-001) in the treatment of IBS and its symptoms.
Link: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30056-X/fulltext
DOI: https://doi.org/10.1016/S2468-1253(20)30056-X
Synformulas GmbH
-
DE
-
2021On CPHI since
-
3Certificates
-
100 - 249Employees
Other Content from Synformulas GmbH ()
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance